DermTech Gross Profit

The latest gross profit for DMTK is $1.3M as of March 2024. That compares with $140K in the prior-year period — up 859.0% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside DermTech's historical trend and sector peers before judging valuation or financial health.

Over the past year, DMTK's gross profit moved from $140K to $1.3M — a 859.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in DermTech's operating scale or balance-sheet position.

Against Healthcare companies, DMTK currently prints $1.3M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at DermTech's growth, margins, and balance sheet.

A gross profit figure of $1.3M for DMTK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting DMTK's gross profit ($1.3M), review year-over-year change from $140K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.